Ro 48-8071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: Comparison to simvastatin

Journal of Lipid Research

Volumn 38, Issue 2, 1997, Pages 373-390

  Morand, Olivier H ^a   Aebi, Johannes D ^a   Dehmlow, Henrietta ^a   Ji, Yu Hua ^a   Gains, Nigel ^a   Lengsfeld, Hans ^a   Himber, Jacques ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

coenzyme Q; coronary heart disease; dioxidosqualene; epoxycholesterol; HMG CoA reductase; lipoprotein; liver; monoxidosqualene; squalene synthase; statin

Indexed keywords

CHOLESTEROL; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LANOSTEROL SYNTHASE; LOW DENSITY LIPOPROTEIN; RO 488071; SIMVASTATIN; SQUALENE DERIVATIVE; SQUALENE SYNTHASE; UBIDECARENONE; UNCLASSIFIED DRUG; 2,3 OXIDOSQUALENE; 2,3-OXIDOSQUALENE; ACETIC ACID DERIVATIVE; APOLIPOPROTEIN; BENZOPHENONE DERIVATIVE; DRUG DERIVATIVE; LANOSTEROL; LIPOPROTEIN; MEVINOLIN; MUTASE; RO 48 8071; RO 48-8071; SQUALENE; TRIACYLGLYCEROL; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYPOCHOLESTEROLEMIA; LIVER TOXICITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SQUIRREL MONKEY; SWINE; SYRIAN HAMSTER; ANIMAL; BIOSYNTHESIS; BLOOD; CEBIDAE; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HAMSTER; HEART MUSCLE; LIVER; METABOLISM; MINIPIG; OSMOLARITY; SYNTHESIS;

ACETATES; ANIMALS; APOLIPOPROTEINS; BENZOPHENONES; CHOLESTEROL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INTRAMOLECULAR TRANSFERASES; LANOSTEROL; LIPOPROTEINS; LIVER; LOVASTATIN; MYOCARDIUM; OSMOLAR CONCENTRATION; SAIMIRI; SIMVASTATIN; SQUALENE; SWINE; SWINE, MINIATURE; TRIGLYCERIDES; TUMOR CELLS, CULTURED; UBIQUINONE;

EID: 0030615072     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Sacks, F. M., M. A. Pfeffer, and E. Braunwald. 1995. A symposium, cholesterol-lowering trials: new results and emerging issues. Am. J. Cardiol. 76 (suppl.): 1-126.
2. Pedersen, T. R., J. Kjekshus, K. Berg, T. Haghfelt, O. Faergeman, G. Thorgeirsson, K. Pyörälä, T. Miettinen, L. Wilhelmsen, G. Olsson, and H. Wedel. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-1389.
3. Sheperd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. Macfarlane, J. H. McKillop, and C. J. Packard, for the West of Scotland coronary prevention study group. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301-1307.
4. Pyörälä, K., G. Debacker, I. Graham, P. Poole-Wilson, and D. Wood. 1994. Prevention of coronary heart disease in clinical practice, recommendation of the task-force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 110: 121-161.
5. Pedersen, T. R., and J. A. Tobert. 1996. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. Drug Safety. 14: 11-24.
6. Mölgaard, J., B. L., Lundh, H. von Schenck, and A. G. Olsson. 1991. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia. Atherosclerosis. 91 (suppl.): 21-28.
7. Mitchel, Y. B. 1992. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis. 97 (suppl.): 33-39.
8. Nawrocki, J. W., S. R. Weiss, M. H. Davidson, D. L. Sprecher, S. L. Schwartz, P. J. Lupien, P. H. Jones, H. E. Haber, and D. M. Black. 1995. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15: 678-682.
9. Schafer, W. R., and J. Rine. 1992. Protein prenylation: genes, enzymes, targets and functions. Annu. Rev. Genet. 30: 209-237.
10. Ghirlanda, G., A. Oradei, A. Manto, S. Lippa, L. Uccioli, S. Caputo, A. V. Greco, and G. P. Littarru. 1993. Evidence of plasma CoQ10 lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33: 226-229.
11. Langan, T. J., and M. C. Slater. 1991. Isoprenoids and astroglial cell cycling: diminished mevalonate availability and inhibition of dolichol-linked glycoprotein synthesis arrest cycling through distinct mechanisms. J. Cell. Physiol. 149: 284-292.
12. Jakobisiak, M., S. Bruno, J. S. Skierski, and Z. Darzynkiewicz. 1991. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA. 88: 3628-3632.
13. Kornbrust, D. J., J. S. MacDonald, C. P. Peter, D. M. Duchai, R. J. Stubbs, J. I. Germerhausen, and A. W. Alberts. 1989. Toxicity of the HMG-CoA reductase inhibitor lovastatin, to rabbits. J. Pharmacol. Exp. Ther. 248: 498-505.
14. Oms, P., N. Assie, F. Bruniquel, A. D. Degryse, G. van Haverbeke, and A. Delhon. 1995. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-CoA reductase inhibitor, simvastatin: prevention and reversibility by mevalonate. Pharmacol. Toxicol. 77: 391-396.
15. Brown, M. S., J. R. Faust, and J. L. Goldstein. 1978. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 253: 1121-1128.
16. Stone, B. G., C. D. Evans, W. F. Prigge, W. C. Duane, and R. L. Gebhard. 1989. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects. J. Lipid Res. 30: 1943-1952.
17. Cohen, L. H., A. Van Vliet, L. Roodenburg, L. M. C. Jansen, and M. Griffioen. 1993. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line HepG2 less than simvastatin and lovastatin, which is reflected in the up regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Biochem. Pharmacol. 45: 2203-2208.
18. Fujiyoka, T., F. Nara, Y. Tsujita, J. Fukushige, M. Fukami, and M. Kuroda. 1995. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim. Biophys. Acta. 1254: 7-12.
19. Cattel, L., M. Ceruti, F. Viola, L. Delprino, G. Balliano, A. Duriatti, and P. Bouvier-Navé. 1986. The squalene-2,3-epoxide cyclase as a model for the development of new drugs. Lipids. 21: 31-38.
20. Nelson, J. A., S. R. Steckbeck, and T. A. Spencer. 1981. Biosynthesis of 24,25-epoxycholesterol from squalene 2,3; 22,23-dioxide. J. Biol. Chem. 256: 1067-1068.
21. Spencer, T. A., A. K. Gayen, S. Phirwa, J. A. Nelson, F. R. Taylor, A. K. Kandutsch, and S. K. Erickson. 1985. 24(S),25-Epoxycholesterol: evidence consistent with a role in the regulation of hepatic cholesterogenesis. J. Biol. Chem. 260: 13391-13394.
22. Panini, D. M., T. A. Delate, and M. Sinensky. 1992. Posttranscriptional regulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 24(S),25-oxidolanosterol. J. Biol. Chem. 267: 12647-12654.
23. Taylor, F. R., A. A. Kandutsch, A. K. Gayen, J. A. Nelson, S. Steckbeck-Nelson, S. Phirwa, and T. A. Spencer. 1986. 24,25-Epoxysterol metabolism in cultured mammalian cells and repression of 3-hydroxy-3-methylglutaryl-CoA reductase. J. Biol. Chem. 261: 15039-15044.
24. Dolis, D., and F. Schuber. 1994. Effects of a 2,3-oxidosqualene-lanosterol cyclase inhibitor, 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on the regulation of cholesterol biosynthesis in human hepatoma cell line Hep-G2. Biochem. Pharmacol. 48: 49-57.
25. Ness, G. C., S. Eales, D. Lopez, and Z. Zhao. 1994. Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase gene expression by sterols and nonsterols in rat liver. Arch. Biochem. Biophys. 308: 420-425.
26. Spencer, T. A. 1994. The squalene dioxide pathway of steroid biosynthesis. Acc. Chem. Res. 27: 83-90.
27. Mark, M., P. Müller, R. Maier, and B. Eisele. 1996. Effects of a novel 2,3 oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J. Lipid Res. 37: 148-158.
28. 0 0410359A1, F. Hoffmann-La Roche AG, Basel, Switzerland.
29. 0 0464465A1, F. Hoffmann-La Roche AG, Basel, Switzerland.
30. Jolidon, S., A. Polak-Wyss, P. G. Hartman, and P. Guerry, 1993. 2,3-Oxidosqualene-lanosterol cyclase: an attractive target for antifungal drug design. In Recent Advances in the Chemistry of Anti-Infective Agents. P. H Bentley and R. Ponsford, editors. Bookcraft Ltd, Bath, UK. 223-233.
31. 0 0636367A1, F. Hoffmann-La Roche AG, Basel, Switzerland.
32. Morand, O. H., J. Aebi, P. Guerry, P. G. Hartman, U. Hennes, J. Himber, Y. H. Ji, S. Jolidon, and H. Lengsfeld. 1994. Potent inhibitors of mammalian 2,3-oxidosqualene:lanosterol cyclase are orally active cholesterol lowering agents. Atherosclerosis. 109 (suppl.): 321.
33. Ceruti, M., G. Balliano, F. Viola, L. Cattel, N. Gerst, and F. Schuber. 1987. Synthesis and biological activity of azasqualenes, bis-azasqualenes and derivatives. Eur. J. Med. Chem. 22: 199-208.
34. Panini, S. R., A. Gupta, R. C. Sexton, E. J. Parish, and H. Rudney. 1987. Regulation of sterol biosynthesis and 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in cultured cells by progesterone. J. Biol. Chem. 262: 14435-14440.
35. Panini, S. R., R. C. Sexton, A. K. Gupta, E. J. Parish, S. Chitrakorn, and H. Rudney. 1986. Regulation of 3-hydroxy-3-methylglutaryl-coenzymeA reductase activity and cholesterol biosynthesis by oxylanosterols. J. Lipid Res. 27: 1190-1204.
36. Nadeau, R. G., and R. P. Hanzlik. 1969. Synthesis of labeled squalene and squalene 2,3-oxide. Methods Enzymol. 15: 346-351.
37. Harder, H. E. 1983. Zur Biosynthese der Amyrine: Rolle von Phyllanthol und Wirkung der Cyclase auf 28-Nor-2,3-epoxysqualen. Eidg. Technische Hochschule, Zürich. Dissertation no7429.
38. Van der Hoeven, T. A., and M. Coon. 1974. Preparation and properties of partially purified cytochrome P450 and reduced nicotinamide adenine dinucleotide phosphate cytochrome P450 reductase from rabbit liver microsomes. J. Biol. Chem. 249: 6302-6310.
39. Barton, D. H. R., T. R. Jarman, K. C. Watson, D. A. Widdowson, R. B. Boar, and K. Damps. 1975. Investigations on the biosynthesis of steroids and terpenoids. Part XII. Biosynthesis of 3β-hydroxy-triterpenoids and -steroids from (3S)-2,3-epoxy-2,3-dihydrosqualene. J. Chem. Soc. Perkin Trans. 1: 1134-1138.
40. Panini, S. R., G. T. Everson, and T. A. Spencer. 1991. Effects of specific inhibition of sterol biosynthesis on the uptake and utilization of low density lipoprotein cholesterol by HepG2 cells. J. Lipid Res. 32: 1657-1665.
41. Himber, J., B. Missano, M. Rudling, U. Hennes, and H.J. Kempen. 1995. Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J. Lipid Res. 36: 1567-1585.
42. Okamoto, T., K. Fukui, M. Nakamoto, and T. Kishi. 1985. HPLC of coenzyme Q-related compounds and its application to biological materials. J. Chromatogr. 342: 35-46.
43. Ingebritsen, T. S., and D. M. Gibson. 1981. Assay that modulate S-3-hydroxy-3-methylglutaryl-CoA reductase by reversible phosphorylation. Methods Enzymol. 71: 486-497.
44. Tait, R. M. 1992. Development of a radiometric spot-wash assay for squalene synthase. Anal. Biochem. 203: 310-316.
45. Nagata, Y., and D. B. Zilversmit. 1987. Blockade of intestinal lipoprotein clearance in rabbits injected with Triton WR 1339-ethyl oleate. J. Lipid Res. 28: 684-692.
46. Groot, P. H. E., N. J. Pearce, K. E. Suckling, and S. Eisenberg. 1992. Effects of cholestyramine on lipoprotein levels and metabolism in Syrian hamsters. Biochim. Biophys. Acta. 1123: 76-84.
47. Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260: 212-221.
48. 2-macroglobulin-recognition site. Biochem. J. 279: 863-870.
49. Matthews, C. M. E. 1957. The theory of tracer experiments with I-131 labeled plasma proteins. Phys. Med. Biol. 2: 36-53.
50. Moore, W. R. and G. L. Schatzman. 1992. Purification of 2,3-oxidosqualene cyclase from rat liver. J. Biol. Chem. 267: 22003-22006.
51. Kusano, M., M. Shibuya, U. Sankawa, and Y. Ebizuka. 1995. Molecular cloning of cDNA encoding rat 2,3-oxidosqualene:lanosterol cyclase. Biol. Pharm. Bull. 18: 195-197.
52. Amin, D., S. Gustafson, and M. H. Perrone. 1988. Lovastatin is hypertriglyceridemic in Syrian Golden hamsters. Biochem. Biophys. Res. Commun. 157: 530-534.
53. Grünler, J., J. Ericson, and G. Dallner. 1994. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim. Biophys. Acta. 1212: 259-277.
54. Willis, R. A., K. Folkers, J. L. Tucker, C. Q. Ye, L. J. Xia, and H. Tamagawa. 1990. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA. 87: 8928-8930.
55. Bargossi, A. M., G. Grossi, P. L. Fiorella, A. Gaddi, R. Di Giulio, and M. Battino. 1994. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol. Aspects Med. 15(suppl.): 187-193.
56. Watts, G. F., C. Castelluccio, C. Rice-Evans, N. A. Taub, H. Baum, and P. J. Quinn. 1993. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J. Clin. Pathol. 46: 1055-1057.
57. Shimizu, S. I., T. Yamamoto, H. Sugawara, Y. Kawahara, and K. Momose. 1991. Possible involvement of 3-hydroxy-3-methylglutaryl-CoA reductase in determining the side-chain length of ubiquinone in rat heart. Arch. Biochem. Biophys. 284: 35-39.
58. Belichard, P., D. Pruneau, and A. Zhiri. 1993. Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. Biochim. Biophys. Acta. 1169: 98-102.
59. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-430.
60. Abe, I., M. Rohmer, and G. D. Prestwich. 1993. Enzymatic cyclization of squalene and oxidosqualene to sterol and triterpenes. Chem. Rev. 93: 2189-2206.
61. Corey, E. J., S. C. Virgil, H. Cheng, C. H. Baker, S. P. T. Matsuda, V. Singh, and S. Sarshar. 1995. New insights regarding the cyclization pathway for sterol biosynthesis from (S)-2,3-oxidosqualene. J. Am. Chem. Soc. 117: 11819-11820.
62. Abe, I., and G. D. Prestwich. 1995. Identification of the active site of vertebrate oxidosqualene cyclase. Lipids. 30: 231-234.
63. Duriatti, A., and F. Schuber. 1988. Partial purification of 2,3-oxidosqualene-lanosterol cyclase from hog-liver. Evidence for a functional thiol residue. Biochem. Biophys. Res. Commun. 151: 1378-1385.
64. Abe, I., and G. D. Prestwich. 1995. Molecular cloning, characterization, and functional expression of rat oxidosqualene cyclase cDNA. Proc. Natl. Acad. Sci. USA. 92: 9274-9278.
65. Gerber, P. R., and K. Mueller. 1995. MAB, a generally applicable molecular force field for structure modeling in medicinal chemistry. J. Comp. Aided Mol. Des. 9: 251-268.
66. Johnson, W. S., S. J. Telfer, S. Cheng, and U. Schubert. 1987. Cation-stabilizing auxiliaries: a new concept in biomimetic polyene cyclization. J. Am. Chem. Soc. 109: 2517-2518.
67. Johnson, W. S., R. A. Buchanan, W. R. Bartlett, F. S. Tham, and R. K. Kullnig. 1993. The fluorine atom as a cation-stabilizing auxiliary in biomimetic polyene cyclisation. III. Use to effect regiospecific control. J. Am. Chem. Soc. 115: 504-515.
68. Boutaud, O., D. Dolis, and F. Schuber. 1992. Preferential cyclization of 2,3(S) :22(S),23-dioxidosqualene by mammalian 2,3-oxidosqualene-lanosterol cyclase. Biochem. Biophys. Res. Commun. 188: 898-904.
69. Bravo, E., A. Cantafora, A. Calcabrini, and G. Ortu. 1994. Why prefer the golden Syrian hamster (Mesocricetus auratus) to the Wistar rat in experimental studies on plasma lipoprotein metabolism? Comp. Biochem. Physiol. 107B: 347-355.
70. Horsmans, Y., J. P. Desager, and C. Harvengt. 1990. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG-CoA reductase inhibitor). Pharmacol. Toxicol. 67: 336-339.
71. Saucier, S. E., A. A. Kandutsch, D. S. Clark, and T. A. Spencer. 1993. Hepatic uptake and metabolism of ingested 24-hydroxycholesterol and 24(S),25-epoxycholesterol. Biochim. Biophys. Acta. 1166: 115-123.
72. Osborne, T. F., M. Bennet, and K. Rhee. 1992. Red25, a protein that binds specifically to the sterol regulatory region in the promoter for 3-hydroxy-3-methylglutaryl-CoA reductase. J. Biol. Chem. 267: 18973-18982.
73. Peffley, D. M. 1992. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevalonate: the role of posttranscriptional control. Somat. Cell Mol. Genet. 18: 19-32.
74. Giron, M. D., C. Havel, and J. A. Watson. 1994. Mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase function in α-toxin-perforated cells. Proc. Natl Acad. Sci. USA. 91: 6398-6402.
75. Correll, C. C., L. Ng, and P. A. Edwards. 1994. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase. J. Biol. Chem. 269: 17390-17393.
76. Jiang, G., T. L. McKenzie, D. G. Conrad, and I. Schechter. 1993. Transcriptional regulation by lovastatin and 25-hydroxycholesterol in Hep-G2 cells and molecular cloning and expression and expression of cDNA for the human squalene synthase. J. Biol. Chem. 268: 12818-12824.
77. Peffley, D. M., and A. K. Gayen. 1997. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Arch. Biochem. Biophys. 337: 251-260.
78. Ness, G. C., Z. Zhao, and R. K. Keller. 1994. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7α hydroxylase. Arch. Biochem. Biophys. 311: 277-285.
79. Kurtz, M. M., V. S. Bansal, R. G. Bostedor, J. I. Germerhausen, J. D. Karkas, S. Vaidya, and J. D. Bergstrom. 1995. Mechanism-based toxicity of a squalene synthase inhibitor, zaragozic acid, in the rat. FASEB J. 9 (suppl.): A1317.